Table 1 Baseline demographic and clinical characteristics of the full-analysis set
| Â | LHQW group (N = 410) | Placebo group (N = 405) | Total (N = 815) |
|---|---|---|---|
Age (yrs), Mean ± SD | 37.8 ± 14.5 | 36.3 ± 13.1 | 37.1 ± 13.8 |
Females, n (%) | 196 (47.8) | 216 (53.3) | 412 (50.6) |
Height (cm), Mean  ± SD | 166.3 ± 9.0 | 165.7 ± 8.4 | 166.0 ± 8.7 |
BMI (kg/m2), Mean  ± SD | 23.6 ± 3.7 | 23.2 ± 3.7 | 23.4 ± 3.7 |
Nationality (region) | |||
 China, n (%) | 249 (60.7) | 249 (61.5) | 498 (61.1) |
 Hong Kong (China), n (%) | 3 (0.7) | 1 (0.2) | 4 (0.5) |
 Vietnam, n (%) | 22 (5.4) | 21 (5.2) | 43 (5.3) |
 Thailand, n (%) | 117 (28.5) | 113 (27.9) | 230 (28.2) |
 Philippine, n (%) | 10 (2.4) | 11 (2.7) | 21 (2.6) |
 Others, n (%) | 9 (2.2) | 10 (2.5) | 19 (2.3) |
Local citizens, n (%) | 368 (89.8) | 357 (88.1) | 725 (89.0) |
Ethnicity | 410 | 405 | 815 |
 Yellow, n (%) | 400 (97.6) | 393 (97.0) | 793 (97.3) |
 Brown, n (%) | 10 (2.4) | 12 (3.0) | 22 (2.7) |
COVID-19Â vaccination | |||
 Primary-series, n (%) | 370 (90.2) | 357 (88.1) | 727 (89.2) |
 Incomplete, n (%) | 18 (4.4) | 27 (6.7) | 45 (5.5) |
 Not vaccinated, n (%) | 22 (5.4) | 21 (5.2) | 43 (5.3) |
Receipt of COVID-19Â vaccines | |||
 Inactivated vaccines | 262 (67.5) | 241 (62.8) | 503 (65.2) |
 Adenovirus vaccines | 55 (14.2) | 57 (14.8) | 112 (14.5) |
 mRNA vaccines | 133 (34.3) | 148 (38.5) | 281 (36.4) |
 Recombinant vaccines | 5 (1.3) | 7 (1.8) | 12 (1.6) |
 Missing information | 23 (5.9) | 25 (6.5) | 48 (6.2) |
Duration of vaccination to enrollment (d) | 194.8 ± 103.7 | 189.8 ± 99.9 | 192.3 ± 101.8 |
Symptoms | |||
 Cough, n (%) | 353 (86.1) | 352 (86.9) | 705 (86.5) |
 Sore throat, n (%) | 330 (80.5) | 342 (84.4) | 672 (82.5) |
 Stuffy or runny nose, n (%) | 313 (76.3) | 319 (78.8) | 632 (77.5) |
 Low energy or tiredness, n (%) | 247 (60.2) | 253 (62.5) | 500 (61.3) |
 Myalgia, n (%) | 221 (53.9) | 220 (54.3) | 441 (54.1) |
Comorbidities | |||
 Hypertension,n% | 34 (8.3) | 23 (5.7) | 57 (7.0) |
 Diabetes,n% | 9 (2.2) | 6 (1.5) | 15 (1.8) |
 Fatty liver disease,n% | 8 (2.0) | 4 (1.0) | 12 (1.5) |
 Dyslipidemia,n% | 7 (1.7) | 5 (1.2) | 12 (1.5) |
 Allrgic rhinitis,n% | 2 (0.5) | 7 (1.7) | 9 (1.1) |
 Charlson's comorbidity score | 0.70 ± 1.08 | 0.59 ± 0.97 | 0.64 ± 1.03 |
 Charlson's comorbidity score ≤ 2, n(%) | 377 (92.0) | 380 (93.8) | 757 (92.9) |
 Charlson's comorbidity score > 2, n(%) | 33 (8.0) | 25 (6.2) | 58 (7.1) |